- Motley Fool•16 hours ago
High dividend yields for CenturyLink, GlaxoSmithKline, and Teva look great, but there's more to the story for these stocks.
- Reuters•2 days ago
Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. Teva, which won U.S. approval in January to make an inhaler similar to Advair, also launched a generic version of its own inhaler, AirDuo RespiClick. AirDuo is not a true generic of Advair, but contains the same two active ingredients, fluticasone propionate and salmeterol.
- Business Wire•3 days ago
Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol
Teva Pharmaceutical Industries Ltd., today announced the simultaneous launch of AirDuo™ RespiClick® inhalation powder and its authorized generic for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist combination.
TEVA : Summary for Teva Pharmaceutical Industries - Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||31.00 x 100|
|Ask||31.23 x 100|
|Day's Range||30.80 - 31.22|
|52 Week Range||30.57 - 57.41|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||444.71|
|Dividend & Yield||1.36 (4.23%)|
|1y Target Est||N/A|